Print
Email
Print Edition Stories
BP hones skills through MIT programs
Carbonrally joins gaming with cutting carbon emissions
Idera Pharmaceuticals Inc. is raising $15 million in a registered direct offering the Cambridge biotech has made with investors.
The offering includes the sale of about 4 million units, made up of one common stock share and a warrant to buy 40 percent of a common stock share, at $3.71 per unit. The stock shares are also priced at $3.71 per share.
The funds Idera (Nasdaq: IDRA) raises from the offering will be used to support clinical development of its Hepatitis C virus infection treatment, called IMO-2125, currently in two Phase 1 trials, and for its autoimmune and inflammatory disease treatment, IMO-3100, currently in Phase 1 trials. Proceeds will also be directed to further drug development aimed at toll-like receptors, described by Idera as components of the immune system that direct immune system responses.
In February, Idera reported good results from a mouse study of a drug to fight high blood cholesterol and triglyceride levels. Like IMO-215, the drug is a toll-like receptor antagonist compound.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
